Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders 2. Written willing to sign a consent form Who Should NOT Join This Trial: 1. Known diagnosis of PD or other neurodegenerative disorder 2. Unequivocal signs of parkinsonism on examination 3. Narcolepsy or other known causes of RBD 4. Moderate to severe obstructive sleep apnea 5. Abnormal neurological or MRI examination Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders 2. Written informed consent Exclusion Criteria: 1. Known diagnosis of PD or other neurodegenerative disorder 2. Unequivocal signs of parkinsonism on examination 3. Narcolepsy or other known causes of RBD 4. Moderate to severe obstructive sleep apnea 5. Abnormal neurological or MRI examination

Treatments Being Tested

DEVICE

PET/CT with 18-FDG

FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.

DEVICE

SPECT : 123 I-FP-CIT (DATSCAN)

DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.

DEVICE

MRI

MRI examination to exclude structural brain anomalies.

Locations (1)

Inselspital, University Clinic for Nuclear Medicine
Bern, Switzerland